

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11701495/publications.pdf>

Version: 2024-02-01

376
papers

155,000
citations

767

119
h-index

91

357
g-index

380
all docs

380
docs citations

380
times ranked

152584
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of pharmacological and nonpharmacological treatments for chronic noncancer pain among people using opioids: a longitudinal cohort study. <i>Pain</i> , 2022, 163, 1049-1059.	4.2	2
2	Comorbidity between mood and substance-related disorders: A systematic review and meta-analysis. <i>Australian and New Zealand Journal of Psychiatry</i> , 2022, 56, 757-770.	2.3	14
3	Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. <i>International Journal of Drug Policy</i> , 2022, 100, 103492.	3.3	22
4	Modeling the population-level impact of opioid agonist treatment on mortality among people accessing treatment between 2001 and 2020 in New South Wales, Australia. <i>Addiction</i> , 2022, 117, 1338-1352.	3.3	11
5	Exposure to childhood trauma increases risk of opioid use disorder among people prescribed opioids for chronic non-cancer pain. <i>Drug and Alcohol Dependence</i> , 2022, 230, 109199.	3.2	9
6	The contribution of unstable housing to HIV and hepatitis C virus transmission among people who inject drugs globally, regionally, and at country level: a modelling study. <i>Lancet Public Health</i> , The, 2022, 7, e136-e145.	10.0	14
7	Self-harm and suicide during and after opioid agonist treatment among primary care patients in England: a cohort study. <i>Lancet Psychiatry</i> , the, 2022, 9, 151-159.	7.4	6
8	Mood and Anxiety Symptoms in Persons Taking Prescription Opioids: A Systematic Review with Meta-Analyses of Longitudinal Studies. <i>Pain Medicine</i> , 2022, 23, 1442-1456.	1.9	14
9	Examining the cost and impact of dosing fees among clients in opioid agonist treatment: Results from a cross-sectional survey of Australian treatment clients. <i>Drug and Alcohol Review</i> , 2022, 41, 841-850.	2.1	7
10	State-Level Prevalence and Associates of Opioid Dependence in the USA. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 3825.	2.6	4
11	The impact of opioid agonist treatment on fatal and non-fatal drug overdose among people with a history of opioid dependence in NSW, Australia, 2001-2018: Findings from the OATS retrospective linkage study. <i>Drug and Alcohol Dependence</i> , 2022, 236, 109464.	3.2	7
12	Self-reported challenges obtaining ongoing prescription opioids among Australians with chronic non-cancer pain. <i>International Journal of Drug Policy</i> , 2022, 105, 103708.	3.3	2
13	The impact of opioid agonist treatment on hospitalisations for injecting-related diseases among an opioid dependent population: A retrospective data linkage study. <i>Drug and Alcohol Dependence</i> , 2022, 236, 109494.	3.2	12
14	Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: The ETHOS Engage Study. <i>Drug and Alcohol Dependence</i> , 2022, 237, 109543.	3.2	6
15	Trends in opioid analgesic utilisation among people with a history of opioid dependence. <i>Drug and Alcohol Dependence</i> , 2022, 238, 109548.	3.2	3
16	Prevalence of mental disorders among people with opioid use disorder: A systematic review and meta-analysis. <i>Drug and Alcohol Dependence</i> , 2022, 238, 109551.	3.2	31
17	Data Resource Profile: The Opioid Agonist Treatment and Safety (OATS) Study, New South Wales, Australia. <i>International Journal of Epidemiology</i> , 2021, 49, 1774-1775.	1.9	10
18	Association between opioid agonist therapy use and HIV testing uptake among people who have recently injected drugs: a systematic review and meta-analysis. <i>Addiction</i> , 2021, 116, 1664-1676.	3.3	9

#	ARTICLE	IF	CITATIONS
19	Hospitalisations for non-fatal overdose among people with a history of opioid dependence in New South Wales, Australia, 2001â€“2018: Findings from the OATS retrospective cohort study. <i>Drug and Alcohol Dependence</i> , 2021, 218, 108354.	3.2	5
20	All-cause and cause-specific mortality among people with regular or problematic cocaine use: a systematic review and meta-analysis. <i>Addiction</i> , 2021, 116, 725-742.	3.3	21
21	Prevalence of childhood maltreatment among people with opioid use disorder: A systematic review and meta-analysis. <i>Drug and Alcohol Dependence</i> , 2021, 219, 108459.	3.2	26
22	Trends in cocaine use, markets and harms in Australia, 2003â€“2019. <i>Drug and Alcohol Review</i> , 2021, 40, 946-956.	2.1	15
23	Genome-wide association study of phenotypes measuring progression from first cocaine or opioid use to dependence reveals novel risk genes. <i>Exploration of Medicine</i> , 2021, 2, 60-73.	1.5	6
24	The next wave? Mental health comorbidities and patients with substance use disorders in under-resourced and rural areas. <i>Journal of Substance Abuse Treatment</i> , 2021, 121, 108189.	2.8	12
25	Retention of opioid agonist treatment prescribers across New South Wales, Australia, 2001â€“2018: Implications for treatment systems and potential impact on client outcomes. <i>Drug and Alcohol Dependence</i> , 2021, 219, 108464.	3.2	10
26	Variations in Long-term Opioid Therapy Definitions: A Systematic Review of Observational Studies Using Routinely Collected Data (2000â€“2019). <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3706-3720.	2.4	5
27	International Association for the Study of Pain Presidential Task Force on Cannabis and Cannabinoid Analgesia: research agenda on the use of cannabinoids, cannabis, and cannabis-based medicines for pain management. <i>Pain</i> , 2021, 162, S117-S124.	4.2	33
28	Pharmaceutical Opioid Use Patterns and Indicators of Extramedical Use and Harm in Adults With Chronic Noncancer Pain, 2012-2018. <i>JAMA Network Open</i> , 2021, 4, e213059.	5.9	4
29	Modelling the intervention effect of opioid agonist treatment on multiple mortality outcomes in people who inject drugs: a three-setting analysis. <i>Lancet Psychiatry</i> , 2021, 8, 301-309.	7.4	20
30	Estimating the risk of suicide associated with mental disorders: A systematic review and meta-regression analysis. <i>Journal of Psychiatric Research</i> , 2021, 137, 242-249.	3.1	76
31	The effect of person, treatment and prescriber characteristics on retention in opioid agonist treatment: a 15-year retrospective cohort study. <i>Addiction</i> , 2021, 116, 3139-3152.	3.3	14
32	Alcohol use among young Australian adults in Mayâ€“June 2020 during the COVID-19 pandemic: a prospective cohort study. <i>Addiction</i> , 2021, 116, 3398-3407.	3.3	34
33	Big data and predictive modelling for the opioid crisis: existing research and future potential. <i>The Lancet Digital Health</i> , 2021, 3, e397-e407.	12.3	21
34	Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence. <i>JAMA Psychiatry</i> , 2021, 78, 979.	11.0	244
35	Unintentional and intentional drug poisoning deaths, Australia, 2012â€“2016: Drug pattern profile and demographic characteristics. <i>Drug and Alcohol Dependence</i> , 2021, 229, 109112.	3.2	6
36	Global, regional, and national sex-specific burden and control of the HIV epidemic, 1990â€“2019, for 204 countries and territories: the Global Burden of Diseases Study 2019. <i>Lancet HIV</i> , 2021, 8, e633-e651.	4.7	56

#	ARTICLE	IF	CITATIONS
37	Using administrative data to predict cessation risk and identify novel predictors among new entrants to opioid agonist treatment. <i>Drug and Alcohol Dependence</i> , 2021, 228, 109091.	3.2	4
38	Hepatitis C virus cascade of care among people who inject drugs in Australia: Factors associated with testing and treatment in a universal healthcare system. <i>Drug and Alcohol Dependence</i> , 2021, 228, 109050.	3.2	9
39	Clinical correlates and outcomes associated with pregabalin use among people prescribed opioids for chronic non-cancer pain: A five-year prospective cohort study. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3092-3104.	2.4	9
40	Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study. <i>Clinical Infectious Diseases</i> , 2021, 73, e69-e78.	5.8	43
41	Association Between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2021, 73, e107-e118.	5.8	39
42	General risks of harm with cannabinoids, cannabis, and cannabis-based medicine possibly relevant to patients receiving these for pain management: an overview of systematic reviews. <i>Pain</i> , 2021, 162, S80-S96.	4.2	32
43	Perceived helpfulness of treatment for alcohol use disorders: Findings from the World Mental Health Surveys. <i>Drug and Alcohol Dependence</i> , 2021, 229, 109158.	3.2	3
44	Previous disorders and depression outcomes in individuals with 12-month major depressive disorder in the World Mental Health surveys. <i>Epidemiology and Psychiatric Sciences</i> , 2021, 30, e70.	3.9	3
45	Development of a Brief Patient-Administered Screening Tool for Prescription Opioid Dependence for Primary Care Settings. <i>Pain Medicine</i> , 2020, 21, e79-e88.	1.9	8
46	The epidemiology of alcohol use disorders cross-nationally: Findings from the World Mental Health Surveys. <i>Addictive Behaviors</i> , 2020, 102, 106128.	3.0	108
47	Prevalence of Injecting Drug Use and Coverage of Interventions to Prevent HIV and Hepatitis C Virus Infection Among People Who Inject Drugs in Canada. <i>American Journal of Public Health</i> , 2020, 110, 45-50.	2.7	44
48	Frequency of health-care utilization by adults who use illicit drugs: a systematic review and meta-analysis. <i>Addiction</i> , 2020, 115, 1011-1023.	3.3	88
49	Opioid use disorder. <i>Nature Reviews Disease Primers</i> , 2020, 6, 3.	30.5	278
50	All-Cause and Cause-Specific Mortality Among People Using Extramedical Opioids. <i>JAMA Psychiatry</i> , 2020, 77, 493.	11.0	83
51	Correlates of indicators of potential extra-medical opioid use in people prescribed opioids for chronic non-cancer pain. <i>Drug and Alcohol Review</i> , 2020, 39, 128-134.	2.1	7
52	Opioid use and harms associated with a sustained-release tapentadol formulation: A post-marketing surveillance study. <i>Drug and Alcohol Dependence</i> , 2020, 206, 107697.	3.2	10
53	Associations between national development indicators and the age profile of people who inject drugs: results from a global systematic review and meta-analysis. <i>The Lancet Global Health</i> , 2020, 8, e76-e91.	6.3	19
54	Depression, post-traumatic stress disorder, suicidality and self-harm among people who inject drugs: A systematic review and meta-analysis. <i>Drug and Alcohol Dependence</i> , 2020, 207, 107793.	3.2	44

#	ARTICLE	IF	CITATIONS
55	Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia. <i>Addiction</i> , 2020, 115, 1295-1305.	3.3	46
56	Frequency of injecting among people who inject drugs: A systematic review and meta-analysis. <i>International Journal of Drug Policy</i> , 2020, 76, 102619.	3.3	21
57	Parental supply of sips and whole drinks of alcohol to adolescents and associations with binge drinking and alcohol-related harms: A prospective cohort study. <i>Drug and Alcohol Dependence</i> , 2020, 215, 108204.	3.2	16
58	Injecting risk behaviours amongst people who inject drugs: A global multi-stage systematic review and meta-analysis. <i>International Journal of Drug Policy</i> , 2020, 84, 102866.	3.3	17
59	A large-scale genome-wide association study meta-analysis of cannabis use disorder. <i>Lancet Psychiatry</i> , 2020, 7, 1032-1045.	7.4	200
60	Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet</i> , 2020, 396, 1204-1222.	13.7	7,664
61	Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. <i>Lancet</i> , 2020, 396, 1223-1249.	13.7	3,928
62	Risk factors for indicators of opioid-related harms amongst people living with chronic non-cancer pain: Findings from a 5-year prospective cohort study. <i>EClinicalMedicine</i> , 2020, 28, 100592.	7.1	16
63	Estimating the contribution of stimulant injection to HIV and HCV epidemics among people who inject drugs and implications for harm reduction: A modeling analysis. <i>Drug and Alcohol Dependence</i> , 2020, 213, 108135.	3.2	20
64	All-Cause and Overdose Mortality Risk Among People Prescribed Opioids: A Systematic Review and Meta-analysis. <i>Pain Medicine</i> , 2020, 21, 3700-3711.	1.9	10
65	Life expectancy of people who are dependent on opioids: A cohort study in New South Wales, Australia. <i>Journal of Psychiatric Research</i> , 2020, 130, 435-440.	3.1	15
66	Generational trends in US opioid-overdose deaths. <i>Nature Medicine</i> , 2020, 26, 651-652.	30.7	8
67	The association between parental supply of alcohol and supply from other sources to young people: a prospective cohort. <i>Addiction</i> , 2020, 115, 2140-2147.	3.3	4
68	Rates, characteristics and manner of cannabis-related deaths in Australia 2000–2018. <i>Drug and Alcohol Dependence</i> , 2020, 212, 108028.	3.2	14
69	The overall effect of parental supply of alcohol across adolescence on alcohol-related harms in early adulthood—a prospective cohort study. <i>Addiction</i> , 2020, 115, 1833-1843.	3.3	10
70	Socio-demographic and ecological factors associated with anti-HCV prevalence in people who inject drugs: A systematic review. <i>Drug and Alcohol Dependence</i> , 2020, 209, 107899.	3.2	3
71	Leveraging genome-wide data to investigate differences between opioid use vs. opioid dependence in 41,176 individuals from the Psychiatric Genomics Consortium. <i>Molecular Psychiatry</i> , 2020, 25, 1673-1687.	7.9	82
72	Global systematic review and ecological analysis of HIV in people who inject drugs: National population sizes and factors associated with HIV prevalence. <i>International Journal of Drug Policy</i> , 2020, 77, 102656.	3.3	20

#	ARTICLE	IF	CITATIONS
73	Association between Mental Disorders and Subsequent Medical Conditions. <i>New England Journal of Medicine</i> , 2020, 382, 1721-1731.	27.0	258
74	Global opioid agonist treatment: a review of clinical practices by country. <i>Addiction</i> , 2020, 115, 2243-2254.	3.3	50
75	Adolescent cannabis use disorders. , 2020, , 111-135.		2
76	Burden of injury along the development spectrum: associations between the Socio-demographic Index and disability-adjusted life year estimates from the Global Burden of Disease Study 2017. <i>Injury Prevention</i> , 2020, 26, i12-i26.	2.4	44
77	Societal issues and policy implications related to the use of cannabinoids, cannabis, and cannabis-based medicines for pain management. <i>Pain</i> , 2020, Publish Ahead of Print, S110-S116.	4.2	10
78	The Mortality After Release from Incarceration Consortium (MARIC): Protocol for a multi-national, individual participant data meta-analysis. <i>International Journal of Population Data Science</i> , 2020, 5, 1145.	0.1	9
79	Concordance between the diagnostic guidelines for alcohol and cannabis use disorders in the draft ICD-11 and other classification systems: analysis of data from the WHO's World Mental Health Surveys. <i>Addiction</i> , 2019, 114, 534-552.	3.3	36
80	Global, regional, and country-level estimates of hepatitis C infection among people who have recently injected drugs. <i>Addiction</i> , 2019, 114, 150-166.	3.3	178
81	Concerns and Help-Seeking Among Patients Using Opioids for Management of Chronic Noncancer Pain. <i>Pain Medicine</i> , 2019, 20, 758-769.	1.9	9
82	Effects of medication-assisted treatment on mortality among opioids users: a systematic review and meta-analysis. <i>Molecular Psychiatry</i> , 2019, 24, 1868-1883.	7.9	215
83	Modelling the potential prevention benefits of a treat-all hepatitis C treatment strategy at global, regional and country levels: A modelling study. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1388-1403.	2.0	11
84	The prevalence of non-fatal overdose among people who inject drugs: A multi-stage systematic review and meta-analysis. <i>International Journal of Drug Policy</i> , 2019, 73, 172-184.	3.3	67
85	The epidemiology of drug use disorders cross-nationally: Findings from the WHO's World Mental Health Surveys. <i>International Journal of Drug Policy</i> , 2019, 71, 103-112.	3.3	45
86	Public health implications of legalising the production and sale of cannabis for medicinal and recreational use. <i>Lancet, The</i> , 2019, 394, 1580-1590.	13.7	224
87	Global patterns of opioid use and dependence: harms to populations, interventions, and future action. <i>Lancet, The</i> , 2019, 394, 1560-1579.	13.7	404
88	Responding to global stimulant use: challenges and opportunities. <i>Lancet, The</i> , 2019, 394, 1652-1667.	13.7	169
89	New psychoactive substances: challenges for drug surveillance, control, and public health responses. <i>Lancet, The</i> , 2019, 394, 1668-1684.	13.7	195
90	Strategies to reduce drug-related harm: responding to the evidence base. <i>Lancet, The</i> , 2019, 394, 1490-1493.	13.7	15

#	ARTICLE	IF	CITATIONS
91	Characteristics and circumstances of heroin and pharmaceutical opioid overdose deaths: Comparison across opioids. <i>Drug and Alcohol Dependence</i> , 2019, 205, 107533.	3.2	23
92	Mental health outcomes associated with the use of amphetamines: A systematic review and meta-analysis. <i>EClinicalMedicine</i> , 2019, 16, 81-97.	7.1	91
93	Reductions in emergency department presentations associated with opioid agonist treatment vary by geographic location: A retrospective study in New South Wales, Australia. <i>Drug and Alcohol Review</i> , 2019, 38, 690-698.	2.1	7
94	Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. <i>Lancet Psychiatry</i> , 2019, 6, 995-1010.	7.4	306
95	Global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017. <i>Lancet HIV</i> , 2019, 6, e831-e859.	4.7	341
96	Parental supply of alcohol as a predictor of adolescent alcohol consumption patterns: A prospective cohort. <i>Drug and Alcohol Dependence</i> , 2019, 204, 107529.	3.2	14
97	The effect of entry and retention in opioid agonist treatment on contact with the criminal justice system among opioid-dependent people: a retrospective cohort study. <i>Lancet Public Health</i> , 2019, 4, e334-e342.	10.0	29
98	Prevalence of HIV, HCV and HBV infection and sociodemographic characteristics of people who inject drugs in China: A systematic review and meta-analysis. <i>International Journal of Drug Policy</i> , 2019, 70, 87-93.	3.3	16
99	Mortality among people with regular or problematic use of amphetamines: a systematic review and meta-analysis. <i>Addiction</i> , 2019, 114, 1738-1750.	3.3	32
100	Alcohol Use Disorders in ICD-11: Past, Present, and Future. <i>Alcoholism: Clinical and Experimental Research</i> , 2019, 43, 1617-1631.	2.4	83
101	Alcohol and parenthood: An integrative analysis of the effects of transition to parenthood in three Australasian cohorts. <i>Drug and Alcohol Dependence</i> , 2019, 197, 326-334.	3.2	28
102	The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 435-444.	8.1	145
103	Cross-national patterns of substance use disorder treatment and associations with mental disorder comorbidity in the WHO World Mental Health Surveys. <i>Addiction</i> , 2019, 114, 1446-1459.	3.3	27
104	Association of Cohort and Individual Substance Use With Risk of Transitioning to Drug Use, Drug Use Disorder, and Remission From Disorder. <i>JAMA Psychiatry</i> , 2019, 76, 708.	11.0	27
105	Antidepressant Use Among People Prescribed Opioids for Chronic Noncancer Pain. <i>Pain Medicine</i> , 2019, 20, 2450-2458.	1.9	12
106	A Global Meta-analysis of the Prevalence of HIV, Hepatitis C Virus, and Hepatitis B Virus Among People Who Inject Drugs—Do Gender-Based Differences Vary by Country-Level Indicators?. <i>Journal of Infectious Diseases</i> , 2019, 220, 78-90.	4.0	29
107	Trends in methamphetamine and opioid use among clients of needle-syringe programs in Queensland, Australia: 2007–2015. <i>Drug and Alcohol Review</i> , 2019, 38, 159-168.	2.1	0
108	Cannabinoids, cannabis, and cannabis-based medicine for pain management: a protocol for an overview of systematic reviews and a systematic review of randomised controlled trials. <i>Pain Reports</i> , 2019, 4, e741.	2.7	18

#	ARTICLE	IF	CITATIONS
109	Longitudinal patterns of amphetamine use from adolescence to adulthood: A latent class analysis of a 20-year prospective study of Australians. <i>Drug and Alcohol Dependence</i> , 2019, 194, 121-127.	3.2	7
110	Exploring Comorbidity Within Mental Disorders Among a Danish National Population. <i>JAMA Psychiatry</i> , 2019, 76, 259.	11.0	374
111	Epidemiology of Substance Use Internationally. <i>Advances in Prevention Science</i> , 2019, , 19-36.	0.3	4
112	The impact of cohort substance use upon likelihood of transitioning through stages of alcohol and cannabis use and use disorder: Findings from the Australian National Survey on Mental Health and Wellbeing. <i>Drug and Alcohol Review</i> , 2018, 37, 546-556.	2.1	13
113	The State of US Health, 1990-2016. <i>JAMA - Journal of the American Medical Association</i> , 2018, 319, 1444.	7.4	1,042
114	Association of parental supply of alcohol with adolescent drinking, alcohol-related harms, and alcohol use disorder symptoms: a prospective cohort study. <i>Lancet Public Health</i> , The, 2018, 3, e64-e71.	10.0	61
115	Longitudinal injecting risk behaviours among people with a history of injecting drug use in an Australian prison setting: The HITS-p study. <i>International Journal of Drug Policy</i> , 2018, 54, 18-25.	3.3	46
116	The associations between psychotic experiences and substance use and substance use disorders: findings from the World Health Organization World Mental Health surveys. <i>Addiction</i> , 2018, 113, 924-934.	3.3	56
117	Accurate identification of opioid overdose deaths using coronial data. <i>Forensic Science International</i> , 2018, 287, 40-46.	2.2	13
118	Knowledge of Opioid Overdose and Attitudes to Supply of Take-Home Naloxone Among People with Chronic Noncancer Pain Prescribed Opioids. <i>Pain Medicine</i> , 2018, 19, 533-540.	1.9	32
119	To what extent do data from pharmaceutical claims underâ€estimate opioid analgesic utilisation in Australia?. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 550-555.	1.9	35
120	Pharmaceutical opioid use and harm in Australia: The need for proactive and preventative responses. <i>Drug and Alcohol Review</i> , 2018, 37, S203-S205.	2.1	32
121	Needle and syringe programmes and opioid substitution therapy for preventing HCV transmission among people who inject drugs: findings from a Cochrane Review and metaâ€analysis. <i>Addiction</i> , 2018, 113, 545-563.	3.3	242
122	Health and wellbeing of Indigenous adolescents in Australia: a systematic synthesis of population data. <i>Lancet</i> , The, 2018, 391, 766-782.	13.7	100
123	Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980â€2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 1736-1788.	13.7	4,989
124	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990â€2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 1923-1994.	13.7	3,269
125	Population and fertility by age and sex for 195 countries and territories, 1950â€2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 1995-2051.	13.7	294
126	Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990â€2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet</i> , The, 2018, 392, 1789-1858.	13.7	8,569

#	ARTICLE	IF	CITATIONS
127	Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet, The</i> , 2018, 392, 1859-1922.	13.7	2,123
128	Transancestral GWAS of alcohol dependence reveals common genetic underpinnings with psychiatric disorders. <i>Nature Neuroscience</i> , 2018, 21, 1656-1669.	14.8	490
129	Combating escalating harms associated with pharmaceutical opioid use in Australia: the POPPY II study protocol. <i>BMJ Open</i> , 2018, 8, e025840.	1.9	17
130	Understanding an emerging treatment population: Protocol for and baseline characteristics of a prospective cohort of people receiving treatment for pharmaceutical opioid dependence. <i>Drug and Alcohol Review</i> , 2018, 37, 887-896.	2.1	5
131	Using routinely collected data to understand and predict adverse outcomes in opioid agonist treatment: Protocol for the Opioid Agonist Treatment Safety (OATS) Study. <i>BMJ Open</i> , 2018, 8, e025204.	1.9	31
132	Current Opioid Access, Use, and Problems in Australasian Jurisdictions. <i>Current Addiction Reports</i> , 2018, 5, 464-472.	3.4	12
133	The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet Psychiatry, the</i> , 2018, 5, 987-1012.	7.4	885
134	Cannabis use and non-cancer chronic pain – Authors' reply. <i>Lancet Public Health, The</i> , 2018, 3, e469.	10.0	1
135	Alcohol use disorder and associated physical health complications and treatment amongst individuals with and without opioid dependence: A case-control study. <i>Drug and Alcohol Dependence</i> , 2018, 188, 304-310.	3.2	4
136	Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. <i>Pain</i> , 2018, 159, 1932-1954.	4.2	321
137	Predictors of transitions across stages of heroin use and dependence prior to treatment-seeking among people in treatment for opioid dependence. <i>Drug and Alcohol Dependence</i> , 2018, 191, 145-151.	3.2	18
138	Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. <i>Lancet Public Health, The</i> , 2018, 3, e341-e350.	10.0	172
139	Amphetamine use in the fourth decade of life: Social profiles from a population-based Australian cohort. <i>Drug and Alcohol Review</i> , 2018, 37, 743-751.	2.1	4
140	Adverse adult consequences of different alcohol use patterns in adolescence: an integrative analysis of data to age 30 years from four Australasian cohorts. <i>Addiction</i> , 2018, 113, 1811-1825.	3.3	43
141	Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. <i>Addiction</i> , 2018, 113, 1905-1926.	3.3	685
142	Mortality trends among people with hepatitis B and C: a population-based linkage study, 1993-2012. <i>BMC Infectious Diseases</i> , 2018, 18, 215.	2.9	22
143	Competing global statistics on prevalence of injecting drug use: why does it matter and what can be done?. <i>Addiction</i> , 2018, 113, 1768-1774.	3.3	11
144	Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet, The</i> , 2018, 392, 1015-1035.	13.7	2,005

#	ARTICLE	IF	CITATIONS
145	Defined daily doses (DDD) do not accurately reflect opioid doses used in contemporary chronic pain treatment. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 587-591.	1.9	39
146	A systematic review of injecting-related injury and disease among people who inject drugs. <i>Drug and Alcohol Dependence</i> , 2017, 171, 39-49.	3.2	163
147	Substance dependence among those without symptoms of substance abuse in the World Mental Health Survey. <i>International Journal of Methods in Psychiatric Research</i> , 2017, 26, .	2.1	13
148	A mapping review of take-home naloxone for people released from correctional settings. <i>International Journal of Drug Policy</i> , 2017, 46, 7-16.	3.3	20
149	New developments and opportunities for preventing hepatitis C virus (HCV) among people who use and inject drugs-announcing an <i>Addiction</i> series. <i>Addiction</i> , 2017, 112, 1126-1127.	3.3	2
150	Trends in new psychoactive substances from surface and "dark" net monitoring. <i>Lancet Psychiatry</i> , 2017, 4, 16-18.	7.4	15
151	Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. <i>The Lancet Global Health</i> , 2017, 5, e1192-e1207.	6.3	1,020
152	Estimating treatment coverage for people with substance use disorders: an analysis of data from the World Mental Health Surveys. <i>World Psychiatry</i> , 2017, 16, 299-307.	10.4	160
153	Trends in heroin and pharmaceutical opioid overdose deaths in Australia. <i>Drug and Alcohol Dependence</i> , 2017, 179, 291-298.	3.2	142
154	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet</i> , 2017, 390, 1084-1150.	13.7	573
155	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet</i> , 2017, 390, 1260-1344.	13.7	1,589
156	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet</i> , 2017, 390, 1151-1210.	13.7	3,565
157	Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet</i> , 2017, 390, 1211-1259.	13.7	5,578
158	Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. <i>Lancet</i> , 2017, 390, 1345-1422.	13.7	1,879
159	Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. <i>The Cochrane Library</i> , 2017, 2017, CD012021.	2.8	158
160	Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. <i>Lancet</i> , 2017, 390, 1423-1459.	13.7	284
161	Estimating the number of adults with severe and persistent mental illness who have complex, multi-agency needs. <i>Australian and New Zealand Journal of Psychiatry</i> , 2017, 51, 799-809.	2.3	15
162	Global, regional, and country-level coverage of interventions to prevent and manage HIV and hepatitis C among people who inject drugs: a systematic review. <i>The Lancet Global Health</i> , 2017, 5, e1208-e1220.	6.3	334

#	ARTICLE	IF	CITATIONS
163	Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. <i>International Journal of Drug Policy</i> , 2017, 47, 51-60.	3.3	54
164	Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. <i>BMJ: British Medical Journal</i> , 2017, 357, j1550.	2.3	1,076
165	Illicit Drugs: Patterns of Use, Dependence, and Contribution to Disease Burden in Developed Countries. , 2017, , 134-145.		2
166	The Burden of Mental Disorders in the Eastern Mediterranean Region, 1990-2013. <i>PLoS ONE</i> , 2017, 12, e0169575.	2.5	102
167	Estimating the number of people who inject drugs in Australia. <i>BMC Public Health</i> , 2017, 17, 757.	2.9	38
168	The extent and correlates of community-based pharmaceutical opioid utilisation in Australia. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 521-538.	1.9	63
169	A synthesis of oral morphine equivalents (OME) for opioid utilisation studies. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 733-737.	1.9	322
170	A cross-sectional study of correlates of imprisonment in opioid-dependent men and women in New South Wales, Australia. <i>Drug and Alcohol Review</i> , 2016, 35, 686-692.	2.1	7
171	Global burden of diseases, injuries, and risk factors for young people's health during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2016, 387, 2383-2401.	13.7	710
172	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1603-1658.	13.7	1,612
173	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1459-1544.	13.7	4,934
174	Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1545-1602.	13.7	5,298
175	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1659-1724.	13.7	4,203
176	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1725-1774.	13.7	571
177	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. <i>Lancet, The</i> , 2016, 388, 1813-1850.	13.7	413
178	Estimating the burden of disease attributable to injecting drug use as a risk factor for HIV, hepatitis C, and hepatitis B: findings from the Global Burden of Disease Study 2013. <i>Lancet Infectious Diseases, The</i> , 2016, 16, 1385-1398.	9.1	223
179	Same-day use of opioids and other central nervous system depressants amongst people who tamper with pharmaceutical opioids: A retrospective 7-day diary study. <i>Drug and Alcohol Dependence</i> , 2016, 166, 125-133.	3.2	11
180	Commentary on Cousins et al. (2016): Accumulating evidence on risk of mortality on and off opioid substitution treatment. <i>Addiction</i> , 2016, 111, 83-84.	3.3	1

#	ARTICLE	IF	CITATIONS
181	Concordance of ICD-11 and DSM-5 definitions of alcohol and cannabis use disorders: a population survey. <i>Lancet Psychiatry</i> , 2016, 3, 673-684.	7.4	47
182	The prevalence and burden of bipolar disorder: findings from the Global Burden of Disease Study 2013. <i>Bipolar Disorders</i> , 2016, 18, 440-450.	1.9	426
183	A systematic review and meta-analysis of racial and ethnic disparities in hepatitis C antibody prevalence in United States correctional populations. <i>Annals of Epidemiology</i> , 2016, 26, 570-578.e2.	1.9	8
184	A Cross-National Examination of Differences in Classification of Lifetime Alcohol Use Disorder Between DSM-IV and DSM-5: Findings from the World Mental Health Survey. <i>Alcoholism: Clinical and Experimental Research</i> , 2016, 40, 1728-1736.	2.4	35
185	Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015. <i>Lancet HIV</i> , 2016, 3, e361-e387.	4.7	461
186	Opioid agonist treatment for pharmaceutical opioid dependent people. <i>The Cochrane Library</i> , 2016, , CD011117.	2.8	148
187	Global Burden Of Disease Studies: Implications For Mental And Substance Use Disorders. <i>Health Affairs</i> , 2016, 35, 1114-1120.	5.2	84
188	Global and National Burden of Diseases and Injuries Among Children and Adolescents Between 1990 and 2013. <i>JAMA Pediatrics</i> , 2016, 170, 267.	6.2	479
189	Prevention, early intervention, harm reduction, and treatment of substance use in young people. <i>Lancet Psychiatry</i> , 2016, 3, 280-296.	7.4	296
190	The increasing global health priority of substance use in young people. <i>Lancet Psychiatry</i> , 2016, 3, 251-264.	7.4	378
191	Why young people's substance use matters for global health. <i>Lancet Psychiatry</i> , 2016, 3, 265-279.	7.4	230
192	The global burden of injury: incidence, mortality, disability-adjusted life years and time trends from the Global Burden of Disease study 2013. <i>Injury Prevention</i> , 2016, 22, 3-18.	2.4	898
193	Addressing the burden of mental, neurological, and substance use disorders: key messages from Disease Control Priorities, 3rd edition. <i>Lancet</i> , 2016, 387, 1672-1685.	13.7	586
194	Effectiveness of needle/syringe programmes and opiate substitution therapy in preventing HCV transmission among people who inject drugs. , 2016, 2016, .		38
195	Global Priorities for Addressing the Burden of Mental, Neurological, and Substance Use Disorders. , 2016, , 1-27.		23
196	Global Burden of Mental, Neurological, and Substance Use Disorders: An Analysis from the Global Burden of Disease Study 2010. , 2016, , 29-40.		16
197	Excess Mortality from Mental, Neurological, and Substance Use Disorders in the Global Burden of Disease Study 2010. , 2016, , 41-65.		24
198	Illicit Drug Dependence. , 2016, , 109-125.		10

#	ARTICLE	IF	CITATIONS
199	The Global Burden of Mental, Neurological and Substance Use Disorders: An Analysis from the Global Burden of Disease Study 2010. PLoS ONE, 2015, 10, e0116820.	2.5	908
200	Potential bias due to outcome-related loss to follow-up in cohort studies on incidence of drug injection: systematic review and meta-analysis. Addiction, 2015, 110, 1247-1257.	3.3	11
201	Jurisdictional differences in opioid use, other licit and illicit drug use, and harms associated with substance use among people who tamper with pharmaceutical opioids. Drug and Alcohol Review, 2015, 34, 611-622.	2.1	10
202	Global Epidemiology of HIV Among Women and Girls Who Use or Inject Drugs. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, S100-S109.	2.1	46
203	Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 743-800.	13.7	4,951
204	Pharmaceutical Opioid Use and Dependence among People Living with Chronic Pain: Associations Observed within the Pain and Opioids in Treatment (POINT) Cohort. Pain Medicine, 2015, 16, 1745-1758.	1.9	78
205	Experience of adjunctive cannabis use for chronic non-cancer pain: Findings from the Pain and Opioids IN Treatment (POINT) study. Drug and Alcohol Dependence, 2015, 147, 144-150.	3.2	97
206	Opioid substitution therapy is associated with increased detection of hepatitis C virus infection: A 15-year observational cohort study. Drug and Alcohol Dependence, 2015, 148, 213-216.	3.2	11
207	Symptom screening scales for detecting major depressive disorder in children and adolescents: A systematic review and meta-analysis of reliability, validity and diagnostic utility. Journal of Affective Disorders, 2015, 174, 447-463.	4.1	182
208	Sexual identity, same-sex partners and risk behaviour among a community-based sample of young people in Australia. International Journal of Drug Policy, 2015, 26, 153-161.	3.3	11
209	Mortality among older adults with opioid use disorders in the Veteran's Health Administration, 2000–2011. Drug and Alcohol Dependence, 2015, 147, 32-37.	3.2	52
210	The impact of blood-borne viruses on cause-specific mortality among opioid dependent people: An Australian population-based cohort study. Drug and Alcohol Dependence, 2015, 152, 264-271.	3.2	15
211	How can data harmonisation benefit mental health research? An example of The Cannabis Cohorts Research Consortium. Australian and New Zealand Journal of Psychiatry, 2015, 49, 317-323.	2.3	20
212	The Pain and Opioids IN Treatment study. Pain, 2015, 156, 231-242.	4.2	104
213	Adolescent substance use and educational attainment: An integrative data analysis comparing cannabis and alcohol from three Australasian cohorts. Drug and Alcohol Dependence, 2015, 156, 90-96.	3.2	82
214	Editorial Commentary: The Impact of Opiate Substitution Therapy and Highly Active Antiretroviral Therapy on Mortality Risk Among People Who Inject Drugs. Clinical Infectious Diseases, 2015, 61, 1166-1168.	5.8	4
215	Mortality risk of opioid substitution therapy with methadone versus buprenorphine: a retrospective cohort study. Lancet Psychiatry, the, 2015, 2, 901-908.	7.4	106
216	Defining populations and injecting parameters among people who inject drugs: Implications for the assessment of hepatitis C treatment programs. International Journal of Drug Policy, 2015, 26, 950-957.	3.3	42

#	ARTICLE	IF	CITATIONS
217	Excess mortality among opioid-using patients treated with oral naltrexone in Australia. <i>Drug and Alcohol Review</i> , 2015, 34, 90-96.	2.1	18
218	Associations between psychotic symptoms and substance use in young offenders. <i>Drug and Alcohol Review</i> , 2015, 34, 673-682.	2.1	21
219	Estimating service demand for respite care among informal carers of people with psychological disabilities in Australia. <i>Australian and New Zealand Journal of Public Health</i> , 2015, 39, 284-292.	1.8	15
220	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990–2013: quantifying the epidemiological transition. <i>Lancet, The</i> , 2015, 386, 2145-2191.	13.7	1,544
221	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. <i>Lancet, The</i> , 2015, 386, 2287-2323.	13.7	2,184
222	Cis-Expression Quantitative Trait Loci Mapping Reveals Replicable Associations with Heroin Addiction in OPRM1. <i>Biological Psychiatry</i> , 2015, 78, 474-484.	1.3	64
223	Monoacylglycerol lipase (MGLL) polymorphism rs604300 interacts with childhood adversity to predict cannabis dependence symptoms and amygdala habituation: Evidence from an endocannabinoid system-level analysis. <i>Journal of Abnormal Psychology</i> , 2015, 124, 860-877.	1.9	39
224	The Burden Attributable to Mental and Substance Use Disorders as Risk Factors for Suicide: Findings from the Global Burden of Disease Study 2010. <i>PLoS ONE</i> , 2014, 9, e91936.	2.5	335
225	Illicit Drugs. , 2014, , .		0
226	Opioid substitution therapy as a strategy to reduce deaths in prison: retrospective cohort study. <i>BMJ Open</i> , 2014, 4, e004666.	1.9	54
227	Reply. <i>Hepatology</i> , 2014, 59, 733-734.	7.3	1
228	Afghanistan has a sizeable problem with opioid use. <i>The Lancet Global Health</i> , 2014, 2, e557-e558.	6.3	3
229	Imprisonment of opioid-dependent people in New South Wales, Australia, 2000–2012: a retrospective linkage study. <i>Australian and New Zealand Journal of Public Health</i> , 2014, 38, 165-170.	1.8	10
230	The Global Burden of Disease projects: What have we learned about illicit drug use and dependence and their contribution to the global burden of disease?. <i>Drug and Alcohol Review</i> , 2014, 33, 4-12.	2.1	75
231	Response to <i>Hser et al.</i> (2014): The necessity for more and better data on the global epidemiology of opioid dependence. <i>Addiction</i> , 2014, 109, 1335-1337.	3.3	3
232	The impact of opioid substitution therapy on mortality post-release from prison: retrospective data linkage study. <i>Addiction</i> , 2014, 109, 1306-1317.	3.3	165
233	A comparative study of opioid substitution therapy utilisation among opioid-dependent men and women. <i>Drug and Alcohol Review</i> , 2014, 33, 499-505.	2.1	3
234	Hepatitis C testing and status among opioid substitution treatment clients in New South Wales. <i>Australian and New Zealand Journal of Public Health</i> , 2014, 38, 160-164.	1.8	9

#	ARTICLE	IF	CITATIONS
235	Factors associated with the timing and onset of cannabis use and cannabis use disorder: Results from the 2007 Australian National Survey of Mental Health and Well-being. Drug and Alcohol Review, 2014, 33, 555-564.	2.1	44
236	Commentary: Improving the mental health and substance use estimates in the Global Burden of Disease study: strengthening the evidence base for public policy. International Journal of Epidemiology, 2014, 43, 296-301.	1.9	10
237	Examining non-AIDS mortality among people who inject drugs. Aids, 2014, 28, S435-S444.	2.2	32
238	Causes of death in a cohort treated for opioid dependence between 1985 and 2005. Addiction, 2014, 109, 90-99.	3.3	92
239	The prognosis of common mental disorders in adolescents: a 14-year prospective cohort study. Lancet, The, 2014, 383, 1404-1411.	13.7	379
240	The global epidemiology and burden of psychostimulant dependence: Findings from the Global Burden of Disease Study 2010. Drug and Alcohol Dependence, 2014, 137, 36-47.	3.2	126
241	The adverse health effects of chronic cannabis use. Drug Testing and Analysis, 2014, 6, 39-45.	2.6	288
242	The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study. Addiction, 2014, 109, 1320-1333.	3.3	308
243	What has been achieved in HIV prevention, treatment and care for people who inject drugs, 2010-2012? A review of the six highest burden countries. International Journal of Drug Policy, 2014, 25, 53-60.	3.3	145
244	A systematic review and meta-analysis of naltrexone implants for the treatment of opioid dependence. Drug and Alcohol Review, 2014, 33, 115-128.	2.1	41
245	Effects of HIV Antiretroviral Therapy on Sexual and Injecting Risk-Taking Behavior: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2014, 59, 1483-1494.	5.8	33
246	Risk behaviours among substance use disorder treatment seekers with and without adult ADHD symptoms. Drug and Alcohol Dependence, 2014, 144, 70-77.	3.2	33
247	Young adult sequelae of adolescent cannabis use: an integrative analysis. Lancet Psychiatry, the, 2014, 1, 286-293.	7.4	354
248	Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2014, 384, 1005-1070.	13.7	786
249	Global, regional, and national levels and causes of maternal mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2014, 384, 980-1004.	13.7	1,230
250	Complex Health Needs in the Youth Justice System: A Survey of Community-Based and Custodial Offenders. Journal of Adolescent Health, 2014, 54, 521-526.	2.5	40
251	A latent class analysis of self-reported clinical indicators of psychosocial stability and adherence among opioid substitution therapy patients: Do stable patients receive more unsupervised doses?. Drug and Alcohol Dependence, 2014, 142, 46-55.	3.2	14
252	Mental and Substance Use Disorders in Sub-Saharan Africa: Predictions of Epidemiological Changes and Mental Health Workforce Requirements for the Next 40 Years. PLoS ONE, 2014, 9, e110208.	2.5	102

#	ARTICLE	IF	CITATIONS
253	Establishing the Melbourne injecting drug user cohort study (MIX): rationale, methods, and baseline and twelve-month follow-up results. <i>Harm Reduction Journal</i> , 2013, 10, 11.	3.2	82
254	Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2013, 382, 1575-1586.	13.7	4,651
255	Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2013, 382, 1564-1574.	13.7	668
256	Engagement with the criminal justice system among opioid-dependent people: a retrospective cohort study. <i>Addiction</i> , 2013, 108, 2152-2165.	3.3	20
257	The contributions of viral hepatitis and alcohol to liver-related deaths in opioid-dependent people. <i>Drug and Alcohol Dependence</i> , 2013, 131, 252-257.	3.2	24
258	The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood. <i>Addiction</i> , 2013, 108, 124-133.	3.3	183
259	ANKK1, TTC12, and NCAM1 Polymorphisms and Heroin Dependence. <i>JAMA Psychiatry</i> , 2013, 70, 325.	11.0	66
260	Cannabis Use and the Development and Maintenance of Psychosis. , 2013, , 517-524.		1
261	Mitigating the risk of HIV infection with opioid substitution treatment. <i>Bulletin of the World Health Organization</i> , 2013, 91, 148-149.	3.3	36
262	Mortality among people who inject drugs: a systematic review and meta-analysis. <i>Bulletin of the World Health Organization</i> , 2013, 91, 102-123.	3.3	362
263	How did we arrive at burden of disease estimates for mental and illicit drug use disorders in the Global Burden of Disease Study 2010?. <i>Current Opinion in Psychiatry</i> , 2013, 26, 376-383.	6.3	20
264	Incidence and prevalence of hepatitis C in prisons and other closed settings: Results of a systematic review and meta-analysis. <i>Hepatology</i> , 2013, 58, 1215-1224.	7.3	263
265	The Global Epidemiology and Contribution of Cannabis Use and Dependence to the Global Burden of Disease: Results from the GBD 2010 Study. <i>PLoS ONE</i> , 2013, 8, e76635.	2.5	235
266	Global Epidemiology of Mental Disorders: What Are We Missing?. <i>PLoS ONE</i> , 2013, 8, e65514.	2.5	148
267	HIV Due to Female Sex Work: Regional and Global Estimates. <i>PLoS ONE</i> , 2013, 8, e63476.	2.5	127
268	Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. <i>BMJ, The</i> , 2012, 345, e5945-e5945.	6.0	363
269	Cannabis and progression to other substance use in young adults: findings from a 13-year prospective population-based study. <i>Journal of Epidemiology and Community Health</i> , 2012, 66, e26-e26.	3.7	82
270	The importance of blood-borne viruses in elevated cancer risk among opioid-dependent people: a population-based cohort study. <i>BMJ Open</i> , 2012, 2, e001755.	1.9	32

#	ARTICLE	IF	CITATIONS
271	Extent of illicit drug use and dependence, and their contribution to the global burden of disease. <i>Lancet, The</i> , 2012, 379, 55-70.	13.7	1,074
272	Health of the world's adolescents: a synthesis of internationally comparable data. <i>Lancet, The</i> , 2012, 379, 1665-1675.	13.7	408
273	Commentary on Kelly & Hulse (2012): Is the comparison of mortality between patients prescribed implanted or oral naltrexone an unbiased and unconfounded comparison?. <i>Addiction</i> , 2012, 107, 1825-1826.	3.3	2
274	Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2012, 380, 2129-2143.	13.7	1,013
275	Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2012, 380, 2197-2223.	13.7	7,061
276	Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2012, 380, 2095-2128.	13.7	11,038
277	Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2012, 380, 2163-2196.	13.7	6,376
278	A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. <i>Lancet, The</i> , 2012, 380, 2224-2260.	13.7	9,397
279	Transitions from Injection-Drug-Use-Concentrated to Self-Sustaining Heterosexual HIV Epidemics: Patterns in the International Data. <i>PLoS ONE</i> , 2012, 7, e31227.	2.5	37
280	Commentary on Mehta et al. (2012): Natural history of injecting drug use. <i>Addiction</i> , 2012, 107, 359-360.	3.3	1
281	Cross-National Comparisons of Sex Differences in Opportunities to Use Alcohol or Drugs, and the Transitions to Use. <i>Substance Use and Misuse</i> , 2011, 46, 1169-1178.	1.4	28
282	Sex differences amongst dependent heroin users: Histories, clinical characteristics and predictors of other substance dependence. <i>Addictive Behaviors</i> , 2011, 36, 27-36.	3.0	88
283	Mortality among cocaine users: A systematic review of cohort studies. <i>Drug and Alcohol Dependence</i> , 2011, 113, 88-95.	3.2	182
284	What data are available on the extent of illicit drug use and dependence globally? Results of four systematic reviews. <i>Drug and Alcohol Dependence</i> , 2011, 117, 85-101.	3.2	114
285	Post-marketing surveillance of buprenorphine-naloxone in Australia: Diversion, injection and adherence with supervised dosing. <i>Drug and Alcohol Dependence</i> , 2011, 118, 265-273.	3.2	62
286	The association between trauma and delusional-like experiences. <i>Psychiatry Research</i> , 2011, 189, 259-264.	3.3	31
287	Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. <i>Lancet, The</i> , 2011, 378, 571-583.	13.7	1,107
288	The association between cannabis use and depression: a review of the evidence. , 2011, , 114-128.		4

#	ARTICLE	IF	CITATIONS
289	Definitions related to the use of pharmaceutical opioids: Extramedical use, diversion, non-adherence and aberrant medication-related behaviours. <i>Drug and Alcohol Review</i> , 2011, 30, 236-245.	2.1	107
290	The availability, diversion and injection of pharmaceutical opioids in South Asia. <i>Drug and Alcohol Review</i> , 2011, 30, 246-254.	2.1	48
291	Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. <i>Addiction</i> , 2011, 106, 32-51.	3.3	669
292	Opioid dependence latent structure: two classes with differing severity?. <i>Addiction</i> , 2011, 106, 590-598.	3.3	22
293	The increasing mortality burden of liver disease among opioid-dependent people: cohort study. <i>Addiction</i> , 2011, 106, 2186-2192.	3.3	56
294	Increasing cancer mortality among opioid-dependent persons in Australia: a new public health challenge for a disadvantaged population. <i>Australian and New Zealand Journal of Public Health</i> , 2011, 35, 220-225.	1.8	51
295	The association between delusional-like experiences, and tobacco, alcohol or cannabis use: a nationwide population-based survey. <i>BMC Psychiatry</i> , 2011, 11, 202.	2.6	46
296	Cannabis and the increased incidence and persistence of psychosis. <i>BMJ: British Medical Journal</i> , 2011, 342, d719-d719.	2.3	19
297	Meth/amphetamine use and associated HIV: Implications for global policy and public health. <i>International Journal of Drug Policy</i> , 2010, 21, 347-358.	3.3	152
298	Improving the data to strengthen the global response to HIV among people who inject drugs. <i>International Journal of Drug Policy</i> , 2010, 21, 100-102.	3.3	14
299	Mental disorders as risk factors for substance use, abuse and dependence: results from the 10-year follow-up of the National Comorbidity Survey. <i>Addiction</i> , 2010, 105, 1117-1128.	3.3	485
300	WHAT ARE THE POLICY IMPLICATIONS OF THE EVIDENCE ON CANNABIS USE AND PSYCHOSIS?. <i>Addiction</i> , 2010, 105, 1332-1333.	3.3	5
301	Does cannabis use increase the risk of death? Systematic review of epidemiological evidence on adverse effects of cannabis use. <i>Drug and Alcohol Review</i> , 2010, 29, 318-330.	2.1	141
302	Early Cannabis Use and Estimated Risk of Later Onset of Depression Spells: Epidemiologic Evidence From the Population-based World Health Organization World Mental Health Survey Initiative. <i>American Journal of Epidemiology</i> , 2010, 172, 149-159.	3.4	64
303	Predictors of social anxiety in an opioid dependent sample and a control sample. <i>Journal of Anxiety Disorders</i> , 2010, 24, 49-54.	3.2	17
304	Is ecstasy a drug of dependence?. <i>Drug and Alcohol Dependence</i> , 2010, 107, 1-10.	3.2	115
305	Evaluating the drug use "gateway" theory using cross-national data: Consistency and associations of the order of initiation of drug use among participants in the WHO World Mental Health Surveys. <i>Drug and Alcohol Dependence</i> , 2010, 108, 84-97.	3.2	228
306	Systematic review of prospective studies investigating "remission" from amphetamine, cannabis, cocaine or opioid dependence. <i>Addictive Behaviors</i> , 2010, 35, 741-749.	3.0	106

#	ARTICLE	IF	CITATIONS
307	HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. <i>Lancet, The</i> , 2010, 375, 1014-1028.	13.7	629
308	Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. <i>Lancet, The</i> , 2010, 376, 285-301.	13.7	382
309	Naloxone for administration by peers in cases of heroin overdose. <i>Medical Journal of Australia</i> , 2009, 191, 469-469.	1.7	23
310	Estimating The Level of HIV Prevention Coverage, Knowledge and Protective Behavior Among Injecting Drug Users: What Does The 2008 UNGASS Reporting Round Tell Us?. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 52, S132-S142.	2.1	22
311	Should Burden of Disease Estimates Include Cannabis Use as a Risk Factor for Psychosis?. <i>PLoS Medicine</i> , 2009, 6, e1000133.	8.4	41
312	Child maltreatment as a risk factor for opioid dependence: Comparison of family characteristics and type and severity of child maltreatment with a matched control group. <i>Child Abuse and Neglect</i> , 2009, 33, 343-352.	2.6	100
313	A systematic review of research examining benzodiazepine-related mortality. <i>Pharmacoepidemiology and Drug Safety</i> , 2009, 18, 93-103.	1.9	87
314	Are adolescents who moderate their cannabis use at lower risk of later regular and dependent cannabis use?. <i>Addiction</i> , 2009, 104, 806-814.	3.3	21
315	Socio-demographic risk factors for alcohol and drug dependence: the 10-year follow-up of the national comorbidity survey. <i>Addiction</i> , 2009, 104, 1346-1355.	3.3	138
316	Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: patient characteristics and patterns and predictors of treatment retention. <i>Addiction</i> , 2009, 104, 1363-1372.	3.3	81
317	Estimating the burden of disease attributable to illicit drug use and mental disorders: what is the Global Burden of Disease 2005 and why does it matter?. <i>Addiction</i> , 2009, 104, 1466-1471.	3.3	20
318	Now is the time to take steps to allow peer access to naloxone for heroin overdose in Australia. <i>Drug and Alcohol Review</i> , 2009, 28, 583-585.	2.1	17
319	Sociodemographic predictors of transitions across stages of alcohol use, disorders, and remission in the National Comorbidity Survey Replication. <i>Comprehensive Psychiatry</i> , 2009, 50, 299-306.	3.1	83
320	Further evidence of differences in substance use and dependence between Australia and the United States. <i>Drug and Alcohol Dependence</i> , 2009, 100, 258-264.	3.2	25
321	Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: Risk factors and lives saved. <i>Drug and Alcohol Dependence</i> , 2009, 105, 9-15.	3.2	309
322	Mortality among amphetamine users: A systematic review of cohort studies. <i>Drug and Alcohol Dependence</i> , 2009, 105, 1-8.	3.2	93
323	Reprint of "Understanding comorbidity between substance use, anxiety and affective disorders: Broadening the research base". <i>Addictive Behaviors</i> , 2009, 34, 795-799.	3.0	15
324	Understanding comorbidity between substance use, anxiety and affective disorders: Broadening the research base. <i>Addictive Behaviors</i> , 2009, 34, 526-530.	3.0	53

#	ARTICLE	IF	CITATIONS
325	Adverse health effects of non-medical cannabis use. <i>Lancet, The</i> , 2009, 374, 1383-1391.	13.7	941
326	The Importance of Timing of Transitions for Risk of Regular Smoking and Nicotine Dependence. <i>Annals of Behavioral Medicine</i> , 2008, 36, 87-92.	2.9	54
327	Exposure to opioid maintenance treatment reduces long-term mortality. <i>Addiction</i> , 2008, 103, 462-468.	3.3	161
328	Adolescent cannabis users at 24 years: trajectories to regular weekly use and dependence in young adulthood. <i>Addiction</i> , 2008, 103, 1361-1370.	3.3	158
329	CANNABIS ABUSE AND DEPENDENCE. , 2008, , 117-148.		4
330	Improving targets for the prevention of drug use disorders: Sociodemographic predictors of transitions across drug use stages in the national comorbidity survey replication. <i>Preventive Medicine</i> , 2008, 47, 629-634.	3.4	27
331	Are diagnostic orphans at risk of developing cannabis abuse or dependence?. <i>Drug and Alcohol Dependence</i> , 2008, 92, 86-90.	3.2	23
332	Assessment of cocaine and other drug dependence in the general population: "Gated" versus "ungated" approaches. <i>Drug and Alcohol Dependence</i> , 2008, 93, 227-232.	3.2	35
333	Global epidemiology of injecting drug use and HIV among people who inject drugs: a systematic review. <i>Lancet, The</i> , 2008, 372, 1733-1745.	13.7	1,107
334	Cannabis use and the risk of developing a psychotic disorder. <i>World Psychiatry</i> , 2008, 7, 68-71.	10.4	109
335	Toward a Global View of Alcohol, Tobacco, Cannabis, and Cocaine Use: Findings from the WHO World Mental Health Surveys. <i>PLoS Medicine</i> , 2008, 5, e141.	8.4	629
336	Cannabis-Induced Psychosis among Aboriginal People in the Northwest Territories. <i>Canadian Journal of Psychiatry</i> , 2007, 52, 475-476.	1.9	0
337	Prevalence and correlates of cannabis use in developed and developing countries. <i>Current Opinion in Psychiatry</i> , 2007, 20, 393-397.	6.3	139
338	The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study. <i>Psychological Medicine</i> , 2007, 37, 927-934.	4.5	79
339	Hospital separations for cannabis and methamphetamine-related psychotic episodes in Australia. <i>Medical Journal of Australia</i> , 2007, 186, 342-345.	1.7	47
340	Assessing cannabis dependence in community surveys: methodological issues. <i>International Journal of Methods in Psychiatric Research</i> , 2007, 16, 43-51.	2.1	31
341	Case ascertainment of alcohol dependence in general population surveys: "gated" versus "ungated" approaches. <i>International Journal of Methods in Psychiatric Research</i> , 2007, 16, 111-123.	2.1	35
342	Who are the new amphetamine users? A 10-year prospective study of young Australians. <i>Addiction</i> , 2007, 102, 1269-1279.	3.3	37

#	ARTICLE	IF	CITATIONS
343	Suicidal behaviour and associated risk factors among opioid-dependent individuals: a case-control study. <i>Addiction</i> , 2007, 102, 1933-1941.	3.3	93
344	Affective disorders, anxiety disorders and psychological distress in non-drinkers. <i>Journal of Affective Disorders</i> , 2007, 99, 165-172.	4.1	23
345	Substance use, dependence and treatment seeking in the United States and Australia: A cross-national comparison. <i>Drug and Alcohol Dependence</i> , 2006, 81, 149-155.	3.2	80
346	What are the Policy Implications of the Evidence on Cannabis and Psychosis?. <i>Canadian Journal of Psychiatry</i> , 2006, 51, 566-574.	1.9	41
347	Is Cannabis Use a Contributory Cause of Psychosis?. <i>Canadian Journal of Psychiatry</i> , 2006, 51, 556-565.	1.9	105
348	Documenting the heroin shortage in New South Wales. <i>Drug and Alcohol Review</i> , 2006, 25, 297-305.	2.1	21
349	Reasons for Cannabis use in Psychosis. <i>Australian and New Zealand Journal of Psychiatry</i> , 2006, 40, 570-574.	2.3	107
350	Effects of a sustained heroin shortage in three Australian States. <i>Addiction</i> , 2005, 100, 908-920.	3.3	121
351	The impact of a reduction in drug supply on demand for and compliance with treatment for drug dependence. <i>Drug and Alcohol Dependence</i> , 2005, 79, 129-135.	3.2	29
352	Age differentials in the impacts of reduced heroin: Effects of a "heroin shortage" in NSW, Australia. <i>Drug and Alcohol Dependence</i> , 2005, 79, 397-404.	3.2	13
353	Is there a specific "cannabis psychosis"? , 2004, , 89-100.		15
354	Cannabis use and psychotic disorders: an update. <i>Drug and Alcohol Review</i> , 2004, 23, 433-443.	2.1	88
355	Patterns of co-morbidity between alcohol use and other substance use in the Australian population. <i>Drug and Alcohol Review</i> , 2003, 22, 7-13.	2.1	61
356	Exploring the association between cannabis use and depression. <i>Addiction</i> , 2003, 98, 1493-1504.	3.3	470
357	Testing hypotheses about the relationship between cannabis use and psychosis. <i>Drug and Alcohol Dependence</i> , 2003, 71, 37-48.	3.2	242
358	The link between cannabis use and psychosis: furthering the debate. <i>Psychological Medicine</i> , 2003, 33, 3-6.	4.5	34
359	Cannabis use and mental health in young people: cohort study. <i>BMJ: British Medical Journal</i> , 2002, 325, 1195-1198.	2.3	809
360	"Diagnostic orphans" among young adult cannabis users: persons who report dependence symptoms but do not meet diagnostic criteria. <i>Drug and Alcohol Dependence</i> , 2002, 67, 205-212.	3.2	48

#	ARTICLE	IF	CITATIONS
361	Cannabis and psychosis. <i>Current Psychiatry Reports</i> , 2002, 4, 191-196.	4.5	64
362	Cannabis dependence in young adults: an Australian population study. <i>Addiction</i> , 2002, 97, 187-194.	3.3	142
363	Substance use disorders in an Australian community survey. <i>Drug and Alcohol Review</i> , 2002, 21, 275-280.	2.1	6
364	The relationship between cannabis use and other substance use in the general population. <i>Drug and Alcohol Dependence</i> , 2001, 64, 319-327.	3.2	140
365	The association between psychosis and problematical drug use among Australian adults: findings from the National Survey of Mental Health and Well-Being. <i>Psychological Medicine</i> , 2001, 31, 659-668.	4.5	167
366	Alcohol, cannabis and tobacco use among Australians: a comparison of their associations with other drug use and use disorders, affective and anxiety disorders, and psychosis. <i>Addiction</i> , 2001, 96, 1603-1614.	3.3	263
367	Cannabis Use and Psychosis: A Review of Clinical and Epidemiological Evidence. <i>Australian and New Zealand Journal of Psychiatry</i> , 2000, 34, 26-34.	2.3	160
368	Cohort trends in the age of initiation of drug use in Australia. <i>Australian and New Zealand Journal of Public Health</i> , 2000, 24, 421-426.	1.8	105
369	Cohort Trends in Youth Suicide in Australia 1964-1997. <i>Australian and New Zealand Journal of Psychiatry</i> , 2000, 34, 408-412.	2.3	21
370	Alcohol- and Drug-Use Disorders in Australia: Implications of the National Survey of Mental Health and Wellbeing. <i>Australian and New Zealand Journal of Psychiatry</i> , 2000, 34, 206-213.	2.3	193
371	The 12-month prevalence of substance use and ICD-10 substance use disorders in Australian adults: findings from the National Survey of Mental Health and Well-Being. <i>Addiction</i> , 1999, 94, 1541-1550.	3.3	145
372	Schizophrenia secondary to cannabis use. , 0, , 169-178.		0
373	Substance Use and Mental Health in Longitudinal Perspective. , 0, , 43-51.		20
374	What are the policy implications of the evidence on cannabis and psychosis?. , 0, , 55-65.		1
375	Drug-Use Disorders. , 0, , 243-262.		3
376	Genome-wide association study of phenotypes measuring progression from first cocaine or opioid use to dependence reveals novel risk genes. <i>Exploration of Medicine</i> , 0, , .	1.5	0